DE3211263C2 - - Google Patents

Info

Publication number
DE3211263C2
DE3211263C2 DE3211263A DE3211263A DE3211263C2 DE 3211263 C2 DE3211263 C2 DE 3211263C2 DE 3211263 A DE3211263 A DE 3211263A DE 3211263 A DE3211263 A DE 3211263A DE 3211263 C2 DE3211263 C2 DE 3211263C2
Authority
DE
Germany
Prior art keywords
leu
ser
peptide
gln
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE3211263A
Other languages
German (de)
English (en)
Other versions
DE3211263A1 (de
Inventor
Fumio Shimizu
Yasukazu Tokushima Jp Ohmoto
Kenichi Itano Tokushima Jp Imagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP56047840A external-priority patent/JPS57163351A/ja
Priority claimed from JP56102731A external-priority patent/JPS582749A/ja
Priority claimed from JP13312881A external-priority patent/JPS5835156A/ja
Priority claimed from JP13312781A external-priority patent/JPS5835158A/ja
Priority claimed from JP56133129A external-priority patent/JPS5835155A/ja
Priority claimed from JP56133124A external-priority patent/JPS5835157A/ja
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of DE3211263A1 publication Critical patent/DE3211263A1/de
Application granted granted Critical
Publication of DE3211263C2 publication Critical patent/DE3211263C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE19823211263 1981-03-31 1982-03-26 Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung Granted DE3211263A1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP56047840A JPS57163351A (en) 1981-03-31 1981-03-31 N-terminal peptide of beta-type interferon
JP56102731A JPS582749A (ja) 1981-06-30 1981-06-30 アフイニテイ−クロマトグラフイ−用吸着体
JP13312881A JPS5835156A (ja) 1981-08-24 1981-08-24 螢光標識ペプチド及びそれを利用するヒトβ型インタ−フエロンの測定法
JP13312781A JPS5835158A (ja) 1981-08-24 1981-08-24 螢光標識ペプチド及びそれを利用するヒトα型インタ−フエロンの測定法
JP56133129A JPS5835155A (ja) 1981-08-24 1981-08-24 ヒトリムホブラストイドインターフェロンのｃ末端ペプチド
JP56133124A JPS5835157A (ja) 1981-08-24 1981-08-24 ヒトリムホブラストイドインターフェロンのｎ末端ペプチド

Publications (2)

Publication Number Publication Date
DE3211263A1 DE3211263A1 (de) 1983-01-27
DE3211263C2 true DE3211263C2 (enFirst) 1987-09-24

Family

ID=27550292

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19823211263 Granted DE3211263A1 (de) 1981-03-31 1982-03-26 Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung

Country Status (6)

Country Link
US (1) US4474754A (enFirst)
CH (1) CH652411A5 (enFirst)
DE (1) DE3211263A1 (enFirst)
FR (1) FR2503145B1 (enFirst)
GB (1) GB2102810B (enFirst)
SE (1) SE457352B (enFirst)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2557458B1 (fr) * 1983-12-30 1987-09-04 Centre Nat Rech Scient Nouveaux anticorps capables de reconnaitre specifiquement des groupements hapteniques, leur preparation et leur application, et nouveaux antigenes permettant de les preparer
US4959457A (en) * 1984-05-31 1990-09-25 Genentech, Inc. Anti-lymphotoxin
US5912136A (en) * 1985-11-19 1999-06-15 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US5700915A (en) * 1985-11-19 1997-12-23 Schering Corporations Human interleukin immunopurification processes
IT8820888A0 (it) * 1988-06-08 1988-06-08 Eniricerche Spa Peptidi di sintesi immunologicamente attivi per lapreparazione di vaccini antimalarici.
DE3841767A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5391713A (en) * 1989-06-20 1995-02-21 Bionative Ab Interferon purification process
SE468251B (sv) * 1989-06-20 1992-11-30 Bionative Ab Reningsprocess foer interferon
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
AU4251300A (en) 1999-05-07 2000-11-21 University Of Virginia Patent Foundation Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
CN1527721A (zh) * 2000-09-12 2004-09-08 基因特罗生物治疗公司 含治疗性蛋白混合物的组合物及其生产方法
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
AU2002246955B2 (en) * 2001-01-09 2007-03-22 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FI20021761A0 (fi) * 2002-10-03 2002-10-03 Karyon Oy Ab Ltd Uusia lääkeaineita ja -valmisteita sekä niiden käyttö
US20050164168A1 (en) * 2003-03-28 2005-07-28 Cullum Malford E. Method for the rapid diagnosis of infectious disease by detection and quantitation of microorganism induced cytokines
CA2536041A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
BRPI0516470A (pt) * 2004-10-07 2008-09-09 Universitot Zuerich uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase
RU2431638C2 (ru) * 2005-02-10 2011-10-20 Бэйлор Рисерч Инститьют Моноклональные антитела против интерферона-альфа и способы применения
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
AU2009245792B2 (en) 2008-05-07 2012-11-01 Coimmune, Inc. Humanized antibodies against human interferon-alpha
EP2719774B8 (en) 2008-11-07 2020-04-22 Adaptive Biotechnologies Corporation Methods of monitoring conditions by sequence analysis
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
HUE029424T2 (en) 2009-01-15 2017-02-28 Adaptive Biotechnologies Corp Adaptive immunity profiling and a method for producing monoclonal antibodies
RU2539032C2 (ru) 2009-06-25 2015-01-10 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения искусственного иммунитета
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
AU2012316279A1 (en) * 2011-09-29 2014-04-17 Janssen Pharmaceutica Nv Process for the preparation of sulfamide derivatives
AU2012325791B2 (en) 2011-10-21 2018-04-05 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
ES2867924T3 (es) 2011-12-09 2021-10-21 Adaptive Biotechnologies Corp Diagnóstico de tumores malignos linfoides y detección de enfermedad residual mínima
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
EP2823060B1 (en) 2012-03-05 2018-02-14 Adaptive Biotechnologies Corporation Determining paired immune receptor chains from frequency matched subunits
DK2831276T3 (da) 2012-05-08 2016-08-01 Adaptive Biotechnologies Corp Sammensætninger og fremgangsmåde til at måle og kalibrere amplifikations-bias i multipleks-PCR-reaktioner
US20160002731A1 (en) 2012-10-01 2016-01-07 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
AU2015227054A1 (en) 2014-03-05 2016-09-22 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP3132059B1 (en) 2014-04-17 2020-01-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341761A (en) * 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
DE3040824A1 (de) * 1980-10-30 1982-08-19 Dr. Karl Thomae Gmbh, 7950 Biberach Neues dekapeptid, verfahren zu seiner herstellung und verwendung
DE3040825A1 (de) * 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung

Also Published As

Publication number Publication date
SE457352B (sv) 1988-12-19
US4474754A (en) 1984-10-02
GB2102810B (en) 1985-03-20
SE8202012L (sv) 1982-10-01
CH652411A5 (de) 1985-11-15
DE3211263A1 (de) 1983-01-27
FR2503145B1 (fr) 1986-12-19
FR2503145A1 (fr) 1982-10-08
GB2102810A (en) 1983-02-09

Similar Documents

Publication Publication Date Title
DE3211263C2 (enFirst)
DE3428942C2 (de) (h-pth)-peptidderivate
DE2858718C2 (enFirst)
JPS6118799A (ja) 効力のあるサイモペンチン類似体
DE3120312C2 (de) Verfahren zur Herstellung von Darm-Glucagon-Antigenen und deren Verwendung
DE3881467T2 (de) Vasokonstriktor-Peptid.
DE3039122A1 (de) Glucagonfragment und seine verwendung
EP0051205B1 (de) Neues Tridekapeptid, Verfahren zu seiner Herstellung und Verwendung
DE2544348A1 (de) L-leucin-13-motilin, verfahren zu dessen herstellung und dasselbe enthaltendes mittel
EP0075776A1 (de) Bis-thymosin Alpha 1-Verbindungen
DE2804566C2 (de) Arginyl-Lysyl-Aspartyl-Valyl-Tyrosin und dessen Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE3151738A1 (de) Peptid fuer die analyse des menschlichen hormons der nebenschilddruese
DE3014582C2 (enFirst)
DE2804567C2 (de) Pentapeptide, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69014042T2 (de) Verfahren zur Herstellung von menschlichem Osteocalcin.
DE68925365T2 (de) PEPTIDE, DIE EPITOPE AUF R-IFN-BETA REPRÄSENTIEREN, ANTIKöRPER DAGEGEN, UND IHRE ANWENDUNG
DE2628006C2 (de) Tridecapeptid, Verfahren zu seiner Herstellung und seine Verwendung
EP0446797B1 (de) Synthetische Peptide, die Sequenzen aus Faktor VIIa enthalten und deren Verwendung
DE2947268C2 (enFirst)
DE3334405A1 (de) Membranassoziierte proteine (mp(pfeil abwaerts)2(pfeil abwaerts)), verfahren zu ihrer gewinnung sowie ihre verwendung
EP0051204A1 (de) Neues Dekapeptid, Verfahren zu seiner Herstellung und Verwendung
AT384812B (de) Verfahren zur herstellung neuer polypeptide
DE2010759C3 (de) Eckige Klammer auf beta- Ala hoch 1- eckige Klammer zu -ACTH (1- 18>NH tief 2, seine Salze mit Säuren und Komplexe mit Schwermetallen und Polyaminosäuren, sowe diese Verbindungen enthaltende Arzneimittel
DE19919149A1 (de) Von Interferon alpha-2 abgeleitete Peptid-Homodimere und Peptid-Heterodimere
DE3718476A1 (de) Verfahren zur herstellung von konjugaten von metallproteinen und neuen derivaten hiervon

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8125 Change of the main classification

Ipc: C07G 7/00

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee